Author

M. Stringhini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 5 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

D. Neri· 5 shared J. C. Mock· 2 shared P. Murer· 2 shared P. Probst· 2 shared A. M. Villa· 1 shared A. Villa· 1 shared B. Gouyou· 1 shared C. Hutmacher· 1 shared

Activity by Year

2019-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

D. Neri

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Engineering murine GITRL for antibody-mediated delivery to tumor-associated blood vessels

J. C. Mock, I. Astiazaran Rascon, M. Stringhini, M. Catalano, D. Neri

This paper develops GITRL-fusion proteins targeting tumor vasculature but finds they fail to show anti-tumor activity in preclinical models.

bioRxiv · Aug 26, 2020 · PreprintCancer Biology

Antibody-mediated delivery of LIGHT to the tumor boosts Natural Killer cells and delays tumor progression

M. Stringhini, J. Mock, V. Fontana, P. Murer, D. Neri

This paper develops a LIGHT-based fusion protein that accumulates in tumors and enhances Natural Killer cell activity, slowing tumor growth in mouse models.

bioRxiv · May 8, 2020Immunology

An engineered 4-1BBL fusion protein with ''activity-on-demand''

J. C. Mock, M. Stringhini, A. M. Villa, D. Neri

This paper describes an engineered antibody-cytokine fusion protein that activates only upon antigen binding, showing potent anti-tumor activity with reduced toxicity in mouse models.

bioRxiv · Apr 29, 2020Cancer Biology

Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen

P. Probst, M. Stringhini, D. Neri

This study shows that immunotherapy of CT26 tumors using cytokine-based treatments leads to an oligoclonal T cell response targeting the AH1 antigen.

bioRxiv · Oct 2, 2019Immunology

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune check-point inhibitors

E. Puca, P. Probst, M. Stringhini, P. Murer, G. Pellegrini, S. Cazzamalli, C. Hutmacher, B. Gouyou, S. Wulhfard, M. Matasci, A. Villa, D. Neri

This paper describes a fusion protein that delivers interleukin-12 to tumors, enhancing NK and CD8+ T cell activity and synergizing with checkpoint inhibitors.

bioRxiv · Jul 3, 2019Cancer Biology